First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...

SIMPONI ARIA (golimumab) 50mg/4mL single-use vial Simponi Aria (golimumab for infusion; Janssen Biotech) has received approval from the FDA for the treatment of adults with moderately to severely ...

Johnson & Johnson’s biotech arm, Janssen Biotech, received an expanded indication for its anti-TNF (tumor necrosis factor) infusion therapy, Simponi Aria (golimumab), for patients with ...

Golimumab 50mg/4mL; soln for IV infusion after dilution; preservative- and latex-free. Simponi Aria (golimumab) Injection is a colorless to light yellow solution available in packs of 1 vial. Each ...

Please provide your email address to receive an email when new articles are posted on . Janssen announced it has received FDA approvals for Simponi Aria for the treatment of adults with psoriatic ...

SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis First Subcutaneous Anti-TNF to Launch ...

HORSHAM, Pa., Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA ® ...

HORSHAM, Pa. — The Food and Drug Administration this week approved expanded labeling for Janssen Biotech’s rheumatoid arthritis treatment Simponi Aria (golimumab for infusion). The revised label now ...

The US Food and Drug Administration (FDA) has approved golimumab (Simponi Aria, Janssen Biotech, Inc), intravenous (IV) formulation in combination with methotrexate, for the treatment of moderately to ...

WHITEHOUSE STATION, N.J. & NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Johnson & Johnson (NYSE: JNJ) and its subsidiary Centocor ...